The AMG Center for ALS at Mass General recently announced, along with Amylyx Pharmaceuticals, Inc., that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study. The team found that AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05), which was the primary outcome of the study.
Both the commercial biotech (Amylyx) and the research center (Mass General) will submit detailed results from the CENTAUR study to a peer-reviewed publication and presentation at a future medical congress.
The Drug: AMX0035
AMX0035 is Amylyx’ first-in-class investigational therapy designed to reduce neuronal death and dysfunction. It targets mitochondrial and endoplasmic reticulum-dependent neuronal degeneration pathways. In clinical trials, AMX0035 has overall been shown to be safe and effective. A preclinical study revealed that AMX0035 limited cell death and neurotoxic inflammation in differing ALS models. As reported, CENTAUR had 132 ALS participants to assess the safety and effectiveness of AMX0035. During the study, ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).